Janus kinase 1 – Talk Bio

Actionable Insights Powered by AI

Incyte’s oral HS drug hits study goals, but fails to excite investors

povorcitinib, JAK1 inhibitor, hidradenitis suppurativa, Phase 3 trials, efficacy, investor reaction, regulatory submission